HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series....

ENVISAGE-TAVI AF Trial: What Anticoagulant Should We Use?

Between 15% and 30% of patients undergoing TAVR present atrial fibrillation. Many of them have suffered ischemic...

Evolution at 1 Year for the PARTNER 3 Mitral Valve-in-Valve Study

At present, the structural failure of mitral bioprostheses due to their deterioration poses a significant challenge. While...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral...

¿What Should We Do About Significant Coronary Lesions in TAVR?

Aortic stenosis and coronary artery disease (CAD) share risk factors, which means significant lesions will coexist in...

Benefit of Cusp overlap method for self‐expanding transcatheter aortic valves

The need for permanent pacemaker implantation (PPM) continues to be one of the main challenges in TAVR,...

TAVI in ≥90 year old patients: as beneficial as in younger patients

Original Title: Should Transcatheter Aortic valve replacement Be Performed in Nonagenarians? Insights from the STS/ACC TVT Registry. Reference:...